News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TradingKey Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Citi has reiterated its Buy rating for Acumen Pharmaceuticals (ABOS.US) and maintained its target price at $4. This continued endorsement suggests the analyst firm sees ongoing potential or stability in the company's financial outlook and stock performance.
This article reports that Acumen Pharmaceuticals Inc. filed a Form 8K for August 12. The brief announcement provides no further details about the content of the filing. The article is from Investing.com and was published on August 12, 2026.
Acumen Pharmaceuticals (NASDAQ:ABOS) reported a quarterly loss of $0.45 per share, missing analyst estimates by $0.09. The company expects top-line Phase II ALTITUDE-AD results for sabirnetug in late 2026 and plans to file an IND for a blood-brain-barrier delivery candidate in mid-2027. Acumen ended …
Acumen Pharmaceuticals provided updates on its Q2 earnings call, confirming it is on track to release top-line results in late 2026 for its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody for early Alzheimer's disease. The company also discussed its enhanced brain delivery …
Acumen Pharmaceuticals Inc (ABOS) has an earnings forecast score of 9.33, ranking 7th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $6.00 for ABOS, with a consensus "STRONG BUY" rating based on 6 analyst opinions. The company's …
Acumen Pharmaceuticals (ABOS.US) is scheduled to release its earnings report on August 12. The report will be made public before the market opens. Investors and analysts will be closely watching the company's financial performance.
Acumen Pharmaceuticals, Inc. announced it will report its second-quarter financial results on Wednesday, August 12, 2026, and will host a conference call and webcast to provide a business and financial update. The company is a clinical-stage biopharmaceutical firm focused on developing treatments for Alzheimer's …
Acumen Pharmaceuticals Inc (ABOS) is a clinical-stage biopharmaceutical company focused on developing a disease-modifying treatment for Alzheimer's disease. The company's stock is currently rated as a "Strong Buy" by analysts, with a target price of $7.40, indicating a significant upside potential despite weak fundamentals …
This article focuses on the enterprise value to revenue forward metric for Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS). It appears to be a stub or a data-driven page from TradingView, providing financial information related to the company's valuation. The content primarily consists of navigation links, …
This article details the shareholder structure of Acumen Pharmaceuticals Inc (ABOS), listing major individual and institutional holders as well as shareholder types. It provides a breakdown of proportional ownership by entities like RA Capital Management, LP and Sands Capital Ventures LLC, alongside a historical …
Acumen Pharmaceuticals Inc (ABOS) has a TradingKey Stock Score indicating weak fundamentals but high growth potential and is considered fairly valued within the Biotechnology & Medical Research industry. Analysts have rated it a Strong Buy, with a highest price target of $7.40, suggesting significant …
This article analyzes the valuation of Acumen Pharmaceuticals Inc (ABOS), noting its current valuation score of 6.53, ranking 322 out of 386 in its industry. The company's P/E ratio is -1.15, significantly below its recent high and above its recent low. Key valuation metrics …
Acumen Pharmaceuticals (ABOS) has outperformed its sector and industry year-to-date, with a 19.9% return compared to the Medical group's -1.1% and the Medical - Biomedical and Genetics industry's 1.1%. The stock holds a Zacks Rank of #2 (Buy), and its full-year earnings estimate has …
Acumen Pharmaceuticals presented new data at AAIC 2026, highlighting enhanced brain penetration of its EBD antibodies and key patient experience findings. These presentations suggest progress in developing treatments for neurological conditions, focusing on both the biological efficacy and the patient's perspective. The company's research …
Search by ticker symbol or company name and select a result to open its chart.